Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine

Clinical Neuropharmacology

Volumn 29, Issue 3, 2006, Pages 157-159

  Alonso Navarro, Hortensia ^a   Jiménez Jiménez, Félix Javier ^b,c  

^a HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c NONE   (Spain)

Author keywords

Drug induced; Fasciculations; Myoclonus; Side effects; Topiramate; Tremor

Indexed keywords

AMITRIPTYLINE; CYPROHEPTADINE; DIAZEPAM; DIHYDROERGOTAMINE; DIPYRONE; ELETRIPTAN; FLUOXETINE; GABAPENTIN; HALAZEPAM; IBUPROFEN; KETOROLAC; MIRTAZAPINE; NAPROXEN; PARACETAMOL; PAROXETINE; PETHIDINE; PROPRANOLOL; SUMATRIPTAN; TOPIRAMATE; TRAMADOL; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DIZZINESS; DOSE CALCULATION; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FASCICULATION; FEMALE; HUMAN; MIGRAINE; MIGRAINE WITHOUT AURA; MUSCLE ATROPHY; MUSCLE CRAMP; MYOCLONUS; PARESTHESIA; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WEIGHT REDUCTION; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PATHOPHYSIOLOGY;

FASCICULATION; FEMALE; FRUCTOSE; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; MYOCLONUS; TREMOR;

EID: 33746393382     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000220825.65393.93     Document Type: Article

References (28)

1. Deckers CL, Knoester PD, de Haan FJ, et al. Selection criteria for the clinical use of newer antiepileptic drugs. CNS Drugs 2003;17:405-421.
2. Silberstein SD, Ben-Menachem E, Shank RP, et al. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther 2005;27:154-165.
3. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004;6:57-75.
4. Rosen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache 2001;41(suppl 1):S25-32.
5. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-2538.
6. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002;59:132-134.
7. Nieto-Barrera M. Características e indicaciones del topiramato. Rev Neurol 2002;35(suppl 1):88-95.
8. Gatto EM, Roca MC, Raina G, et al. Low doses of topiramate are effective in essential tremor: a report of three cases. Clin Neuropharmacol 2003;26:294-296.
9. Pahwa R, Lyons KE. Essential tremor: differential diagnosis and current therapy. Am J Med 2003;115:134-142.
10. Lyons KE, Pahwa R, Comella CL, et al. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf 2003;26:461-481.
11. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64:2008-2020.
12. Sechi G, Agnetti V, Sulas FM, et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1023-1027.
13. Siniscalchi A, Mancuso F, Russo E, et al. Spinal myoclonus responsive to topiramate. Mov Disord 2004;19:1380-1381.
14. Mathew NT. Antiepileptic drugs in migraine prevention. Headache 2001;41(suppl 1):18-24.
15. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-975.
16. Martinez HR, Londono O, Cantu-Martinez L, et al. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 2003;43:1080-1084.
17. Edwards KR, Potter DL, Wu SC, et al. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr 2003;8:428-432.
18. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;(3):CD003226.
19. Silberstein SD. Topiramate in migraine prevention. Headache 2005;45(suppl 1):S57-65.
20. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45(suppl 1):S66-73.
21. D'Amico D, Grazzi L, Usai S, et al. Topiramate in migraine profylaxis. Neurol Sci 2005;26(suppl 2):S130-S133.
22. Ribacoba-Montero R, Salas-Puig X. Eficacia y tolerancia del topiramato a largo plazo en la epilepsia refractaria del adulto. Rev Neurol 2002;34:101-105.
23. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-733.
24. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004;3:618-621.
25. Froscher W, Schier KR, Hoffmann M, et al. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 2005;7:237-248.
26. Galicia SC, Lewis SL, Metman LV. Severe topiramate-associated hyperthermia resulting in persistent neurological dysfunction. Clin Neuropharmacol 2005;28:94-95.
27. Gupta M, Rehman N, Bansal J, et al. Topiramate: a new safe and effective antiepileptic. J Indian Med Assoc 2001;99:449-450.
28. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia 1998;39:1115-1118.